Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bio-techne Corp (TECH) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Bio-techne Corp. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 842023.
Total stock buying since 2015: $238,295.
Total stock sales since 2015: $211,729,965.
Total stock option exercises since 2015: $128,315,732.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 35,360 | $1,981,913 | 471,926 | $18,792,422 |
| 2024 | 0 | $0 | 30,400 | $2,289,663 | 160,871 | $4,112,999 |
| 2023 | 0 | $0 | 89,261 | $7,813,728 | 804,149 | $19,079,029 |
| 2022 | 300 | $105,765 | 6,704 | $2,446,923 | 131,527 | $11,605,770 |
| 2021 | 0 | $0 | 212,603 | $93,545,992 | 338,115 | $32,814,686 |
| 2020 | 0 | $0 | 203,677 | $54,137,437 | 277,437 | $22,579,574 |
| 2019 | 700 | $132,530 | 177,870 | $37,927,611 | 224,333 | $14,460,601 |
| 2018 | 0 | $0 | 34,136 | $5,831,411 | 43,372 | $1,560,600 |
| 2017 | 0 | $0 | 18,118 | $2,120,290 | 25,915 | $981,050 |
| 2016 | 0 | $0 | 19,724 | $1,996,586 | 21,666 | $1,293,414 |
| 2015 | 0 | $0 | 16,000 | $1,638,411 | 20,218 | $1,035,587 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-05-29 | Eansor Norman David (President-Protein Sciences) | Sale | 7,909 | 262.31 | 2,074,649 |
| 2020-05-29 | Eansor Norman David (President-Protein Sciences) | Option Ex | 7,909 | 108.49 | 858,047 |
| 2020-05-29 | Wiens Harold J | Sale | 3,985 | 260.00 | 1,036,100 |
| 2020-05-29 | Wiens Harold J | Option Ex | 3,985 | 101.19 | 403,242 |
| 2020-05-28 | Furlow Brenda S. (SVP - General Counsel) | Sale | 5,995 | 260.05 | 1,558,999 |
| 2020-05-28 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 7,595 | 101.42 | 770,284 |
| 2020-05-28 | Eansor Norman David (President-Protein Sciences) | Sale | 3,448 | 260.19 | 897,135 |
| 2020-05-28 | Eansor Norman David (President-Protein Sciences) | Option Ex | 3,448 | 108.49 | 374,073 |
| 2020-05-26 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 21,159 | 86.25 | 1,824,963 |
| 2020-05-22 | Eansor Norman David (President-Protein Sciences) | Sale | 12,600 | 268.02 | 3,377,001 |
| 2020-05-22 | Eansor Norman David (President-Protein Sciences) | Option Ex | 12,600 | 101.42 | 1,277,892 |
| 2020-05-21 | Eansor Norman David (President-Protein Sciences) | Sale | 11,037 | 268.13 | 2,959,317 |
| 2020-05-21 | Eansor Norman David (President-Protein Sciences) | Option Ex | 11,037 | 94.35 | 1,041,340 |
| 2020-05-21 | Baumgartner Robert V (Director) | Sale | 5,000 | 266.67 | 1,333,355 |
| 2020-05-21 | Baumgartner Robert V (Director) | Option Ex | 5,000 | 70.35 | 351,750 |
| 2020-05-06 | Wiens Harold J | Sale | 4,260 | 250.00 | 1,065,000 |
| 2020-05-06 | Wiens Harold J | Option Ex | 4,260 | 87.34 | 372,068 |
| 2020-05-01 | Kelderman Kim (Pres. Diagnostics & Genom) | Option Ex | 1,666 | .00 | 0 |
| 2020-04-30 | Wiens Harold J (Director) | Sale | 4,000 | 225.00 | 900,000 |
| 2020-04-30 | Wiens Harold J (Director) | Option Ex | 4,000 | 91.78 | 367,120 |
| 2020-03-04 | Eansor Norman David (President-Protein Sciences) | Sale | 1,387 | 198.68 | 275,569 |
| 2020-02-12 | Higgins John L (Director) | Sale | 5,000 | 205.23 | 1,026,135 |
| 2020-02-12 | Higgins John L (Director) | Option Ex | 5,000 | 61.46 | 307,300 |
| 2020-01-06 | Kummeth Charles R. (Chief Executive Officer) | Sale | 10,276 | 217.28 | 2,232,769 |
| 2020-01-06 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 10,276 | 67.46 | 693,218 |
| 2020-01-03 | Kummeth Charles R. (Chief Executive Officer) | Sale | 7,999 | 217.80 | 1,742,182 |
| 2020-01-03 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 7,999 | 67.46 | 539,612 |
| 2020-01-02 | Kummeth Charles R. (Chief Executive Officer) | Sale | 19,843 | 219.31 | 4,351,748 |
| 2020-01-02 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 19,843 | 67.46 | 1,338,608 |
| 2019-12-24 | Kummeth Charles R. (Chief Executive Officer) | Sale | 471 | 222.18 | 104,648 |
| 2019-12-24 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 471 | 67.46 | 31,773 |
| 2019-12-23 | Kummeth Charles R. (Chief Executive Officer) | Sale | 659 | 222.08 | 146,350 |
| 2019-12-23 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 659 | 67.46 | 44,456 |
| 2019-12-20 | Kummeth Charles R. (Chief Executive Officer) | Sale | 11,534 | 222.06 | 2,561,262 |
| 2019-12-20 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 11,534 | 67.46 | 778,082 |
| 2019-12-12 | Furlow Brenda S. (SVP - General Counsel) | Sale | 8,000 | 215.56 | 1,724,488 |
| 2019-12-12 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 8,000 | 94.35 | 754,800 |
| 2019-12-10 | Kummeth Charles R. (Chief Executive Officer) | Sale | 703 | 222.01 | 156,073 |
| 2019-12-10 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 703 | 67.46 | 47,424 |
| 2019-12-04 | Wiens Harold J (Director) | Sale | 2,000 | 217.96 | 435,914 |
| 2019-12-04 | Wiens Harold J (Director) | Option Ex | 2,000 | 87.83 | 175,660 |
| 2019-11-29 | Kummeth Charles R. (Chief Executive Officer) | Sale | 100 | 222.62 | 22,262 |
| 2019-11-27 | Kummeth Charles R. (Chief Executive Officer) | Sale | 11,772 | 222.12 | 2,614,820 |
| 2019-11-27 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 11,772 | 67.46 | 794,139 |
| 2019-11-25 | Nusse Roeland (Director) | Sale | 8,347 | 219.33 | 1,830,730 |
| 2019-11-25 | Nusse Roeland (Director) | Option Ex | 15,000 | 60.96 | 914,400 |
| 2019-11-22 | Hippel James (Chief Financial Officer) | Sale | 23,651 | 215.85 | 5,105,115 |
| 2019-11-22 | Hippel James (Chief Financial Officer) | Option Ex | 23,651 | 94.35 | 2,231,471 |
| 2019-11-21 | Hippel James (Chief Financial Officer) | Sale | 11,349 | 215.36 | 2,444,131 |
| 2019-11-21 | Hippel James (Chief Financial Officer) | Option Ex | 11,349 | 94.35 | 1,070,778 |
| 2019-09-09 | Kummeth Charles R. (Chief Executive Officer) | Buy | 200 | 185.00 | 37,000 |
| 2019-08-19 | Hippel James (Chief Financial Officer) | Option Ex | 4,925 | .00 | 0 |
| 2019-08-19 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 24,979 | .00 | 0 |
| 2019-08-19 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 1,759 | .00 | 0 |
| 2019-08-19 | Eansor Norman David (SVP - Novus Biologicals) | Option Ex | 2,287 | .00 | 0 |
| 2019-08-13 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 7,410 | 67.46 | 499,878 |
| 2019-08-07 | Baumgartner Robert V (Director) | Buy | 500 | 191.06 | 95,530 |
| 2019-07-10 | Kummeth Charles R. (Chief Executive Officer) | Sale | 16,969 | 213.38 | 3,620,811 |
| 2019-07-10 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 16,969 | 67.46 | 1,144,728 |
| 2019-07-09 | Kummeth Charles R. (Chief Executive Officer) | Sale | 15,037 | 212.43 | 3,194,339 |
| 2019-07-09 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 15,037 | 67.46 | 1,014,396 |
| 2019-07-08 | Kummeth Charles R. (Chief Executive Officer) | Sale | 17,994 | 212.75 | 3,828,187 |
| 2019-07-08 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 17,994 | 67.46 | 1,213,875 |
| 2019-06-12 | Eansor Norman David (SVP - Novus Biologicals) | Sale | 3,117 | 215.00 | 670,155 |
| 2019-05-24 | Furlow Brenda S. (SVP - General Counsel) | Sale | 5,400 | 200.00 | 1,080,000 |
| 2019-05-24 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 5,400 | .00 | 0 |
| 2019-05-01 | Kelderman Kim (President, Diagnostics & Genom) | Option Ex | 1,667 | 202.13 | 336,950 |
| 2019-05-01 | Hippel James (Chief Financial Officer) | Sale | 35,000 | 203.08 | 7,107,695 |
| 2019-05-01 | Hippel James (Chief Financial Officer) | Option Ex | 35,000 | 86.25 | 3,018,750 |
| 2018-08-24 | Baumgartner Robert V | Sale | 5,000 | 188.47 | 942,335 |
| 2018-08-24 | Baumgartner Robert V | Option Ex | 5,000 | 61.46 | 307,300 |
| 2018-08-23 | Higgins John L (Director) | Sale | 10,000 | 187.92 | 1,879,170 |
| 2018-08-23 | Higgins John L (Director) | Option Ex | 10,000 | 61.08 | 610,800 |
| 2018-08-08 | Dinarello Charles A | Sale | 5,000 | 176.94 | 884,675 |
| 2018-08-08 | Dinarello Charles A | Option Ex | 5,000 | 63.03 | 315,150 |
| 2018-08-07 | Hippel James (Chief Financial Officer) | Option Ex | 2,398 | .00 | 0 |
| 2018-08-07 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 13,816 | .00 | 0 |
| 2018-08-07 | Furlow Brenda S. (SVP - General Counsel) | Option Ex | 959 | .00 | 0 |
| 2018-08-07 | Eansor Norman David (SVP - Novus Biologicals) | Option Ex | 1,199 | .00 | 0 |
| 2018-06-07 | Kummeth Charles R. (Chief Executive Officer) | Sale | 8,000 | 160.00 | 1,280,000 |
| 2018-05-04 | Eansor Norman David (SVP - Novus Biologicals) | Sale | 1,136 | 145.19 | 164,931 |
| 2018-02-13 | Dinarello Charles A (Director) | Sale | 5,000 | 136.06 | 680,300 |
| 2018-02-13 | Dinarello Charles A (Director) | Option Ex | 5,000 | 65.47 | 327,350 |
| 2017-11-01 | Baumgartner Robert V | Sale | 5,000 | 130.18 | 650,905 |
| 2017-11-01 | Baumgartner Robert V | Option Ex | 5,000 | 63.03 | 315,150 |
| 2017-10-10 | Lucas Roger C | Sale | 100 | 121.95 | 12,195 |
| 2017-09-08 | Lucas Roger C | Sale | 100 | 120.94 | 12,093 |
| 2017-09-06 | Holbrook Karen A | Sale | 1,059 | 121.73 | 128,908 |
| 2017-08-12 | Kummeth Charles R. (Chief Executive Officer) | Option Ex | 9,248 | .00 | 0 |
| 2017-08-10 | Lucas Roger C | Sale | 100 | 114.30 | 11,430 |
| 2017-07-10 | Lucas Roger C | Sale | 100 | 116.86 | 11,686 |
| 2017-06-09 | Lucas Roger C | Sale | 100 | 113.62 | 11,362 |
| 2017-05-31 | Dinarello Charles A | Sale | 5,000 | 111.37 | 556,860 |
| 2017-05-26 | Dinarello Charles A | Option Ex | 5,000 | 66.59 | 332,950 |
| 2017-05-25 | Holbrook Karen A | Sale | 5,000 | 111.16 | 555,775 |
| 2017-05-25 | Holbrook Karen A | Option Ex | 5,000 | 66.59 | 332,950 |
| 2017-05-22 | Lucas Roger C | Sale | 1,059 | 110.01 | 116,504 |
| 2017-05-10 | Lucas Roger C | Sale | 100 | 110.59 | 11,059 |
| 2017-04-10 | Lucas Roger C | Sale | 100 | 101.18 | 10,118 |
| 2017-03-10 | Lucas Roger C | Sale | 100 | 107.78 | 10,778 |
| 2017-02-10 | Lucas Roger C | Sale | 100 | 102.60 | 10,260 |
| 2017-02-01 | Gavin Robert M. (Senior V.P. Protein Platforms) | Option Ex | 1,667 | .00 | 0 |
| 2017-01-10 | Lucas Roger C | Sale | 100 | 103.57 | 10,357 |
| 2016-12-09 | Lucas Roger C (Director) | Sale | 100 | 108.92 | 10,892 |
| 2016-11-29 | Holbrook Karen A (Director) | Sale | 1,000 | 106.73 | 106,733 |
| 2016-11-16 | Lucas Roger C (Director) | Sale | 100 | 105.75 | 10,575 |
| 2016-10-19 | Lucas Roger C (Director) | Sale | 100 | 104.71 | 10,471 |
| 2016-09-21 | Lucas Roger C (Director) | Sale | 100 | 108.91 | 10,891 |
| 2016-09-08 | Gould Kevin S (SVP Clinical Controls) | Sale | 524 | 110.50 | 57,903 |
| 2016-09-08 | Higgins John L (Director) | Sale | 1,700 | 109.83 | 186,716 |
| 2016-09-02 | Baumgartner Robert V (Director) | Sale | 2,613 | 107.15 | 279,985 |
| 2016-09-02 | Baumgartner Robert V (Director) | Option Ex | 2,613 | 65.47 | 171,073 |
| 2016-09-01 | Baumgartner Robert V (Director) | Sale | 3,854 | 107.17 | 413,052 |
| 2016-09-01 | Baumgartner Robert V (Director) | Option Ex | 3,854 | 66.03 | 254,479 |
| 2016-08-24 | Baumgartner Robert V (Director) | Sale | 3,533 | 107.10 | 378,377 |
| 2016-08-24 | Baumgartner Robert V (Director) | Option Ex | 3,533 | 66.59 | 235,262 |
| 2016-08-17 | Lucas Roger C (Director) | Sale | 100 | 113.70 | 11,370 |
| 2016-07-20 | Lucas Roger C | Sale | 100 | 111.03 | 11,103 |
| 2016-06-15 | Lucas Roger C | Sale | 100 | 112.15 | 11,215 |
| 2016-05-18 | Lucas Roger C | Sale | 100 | 102.53 | 10,253 |
| 2016-05-06 | Lucas Roger C | Sale | 500 | 100.24 | 50,120 |
| 2016-05-05 | Dinarello Charles A | Option Ex | 5,000 | 56.17 | 280,850 |
| 2016-04-20 | Lucas Roger C (Director) | Sale | 100 | 92.40 | 9,240 |
| 2016-03-31 | Hippel James (Chief Financial Officer) | Option Ex | 1,666 | .00 | 0 |
| 2016-03-16 | Lucas Roger C | Sale | 100 | 92.90 | 9,290 |
| 2016-02-05 | Lucas Roger C | Sale | 5,000 | 83.68 | 418,400 |
| 2016-02-05 | Lucas Roger C | Option Ex | 5,000 | 70.35 | 351,750 |
| 2015-08-17 | Lucas Roger C (Director) | Sale | 5,000 | 106.02 | 530,110 |
| 2015-08-17 | Lucas Roger C (Director) | Option Ex | 5,000 | 66.90 | 334,500 |
| 2015-08-13 | Lucas Roger C (Director) | Sale | 5,000 | 106.01 | 530,035 |
| 2015-08-13 | Lucas Roger C (Director) | Option Ex | 5,000 | 61.46 | 307,300 |
| 2015-07-02 | Eansor Norman David (SVP Biotech) | Option Ex | 1,667 | .00 | 0 |
| 2015-06-08 | Veronneau Marcel (SVP - Clinical Controls) | Option Ex | 385 | 79.41 | 30,572 |
| 2015-06-08 | Steer Randolph C (Director) | Sale | 1,000 | 99.39 | 99,386 |
| 2015-03-31 | Hippel James (Chief Financial Officer) | Option Ex | 1,666 | .00 | 0 |
| 2015-02-19 | Oconnell Howard V (Director) | Sale | 5,000 | 95.78 | 478,880 |
| 2015-02-19 | Oconnell Howard V (Director) | Option Ex | 5,000 | 56.17 | 280,850 |
| 2015-02-05 | Dinarello Charles A (Director) | Option Ex | 1,500 | 54.91 | 82,365 |
Insider trading activities including stock purchases, stock sales, and option exercises of TECH listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Bio-techne Corp (symbol TECH, CIK number 842023) see the Securities and Exchange Commission (SEC) website.